70 results about "Respiratory virus infection" patented technology

The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.

The invention relates to a nasal spray preparation for resisting respiratory virus infection. The preparation comprises liposome-loaded angiotensin converting enzyme 2 (ACE2) recombinant protein, sialic acid, natural polysaccharide and normal saline. The nasal spray preparation is mainly prepared from the liposome-loaded ACE2 extracellular domain recombinant protein, can competitively inhibit thecombination of viruses and host cells, prevents and treats respiratory tract infection caused by various viruses, and enhances the antiviral range and clinical indications of the nasal spray preparation for resisting respiratory tract virus infection. In addition, the nasal spray preparation can be used for directly spraying medicines to virus propagation parts, and is convenient and simple to use.

The present invention discloses a kind of medicine powder for intravenous injection and its preparation process. The medicine is prepared with chlorogenic and baicalin as material. The medicine has obvious curative effect on upper respiratory tract infection, pneumonia and viral respiratory tract infection.

The invention discloses a kit used for detecting respiratory viruses and application thereof. A primer pair group used for detecting the respiratory viruses is contained inside the kit and composed of four primer pairs, wherein the sequence of the primer pairs is the sequence 1-8 in a sequence list. The kit supports high flux and can rapidly and accurately detect common respiratory virus infection, detection results of four kinds of virus indexes can be clinically obtained within one hour, the speed is higher than that of a real-time fluorescent quantitation PCR method commonly adopted in the prior art, and the kit has great significance for rapidly assisting in instructing treatment and medication. Meanwhile, detection of multiple indexes can be used for regional epidemic investigation and survey and epidemic situation surveillance and control so that the epidemic situation of respiratory virus infection in China can be researched.

The invention belongs to the technical field of medicines. The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for preventing and treating COVID-19 (diseases caused by novel coronaviruses) and a preparation method thereof. The pharmaceutical composition comprises active ingredients of mycobacterium vaccae for injection and salbutamol sulfate, and the weight ratio of the mycobacterium vaccae for injection to the salbutamol sulfate is 1: (50-200). The medicine prepared from the medicine composition can adopt an aerosol inhalation treatment mode, and through short-term aerosol inhalation, the compliance of a patient can be improved by providing the medicine with a specific purpose for the patient, so that the patient can take the medicine conveniently, and the medical cost is reduced. The pharmaceutical composition for preventing and treating COVID-19 disclosed by the invention has the advantages that the COVID-19 can be effectively prevented and treated; severe or critical symptoms of patients are relieved, nucleic acid negative conversion time is shortened by about 4 days averagely, treatment time is correspondingly shortened, other respiratory virus infections can be prevented and treated nonspecifically, and a new way and scheme are provided for clinical prevention and treatment of COVID-19 and respiratory virus infections.

The invention discloses a traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and a preparation method thereof. The composition comprises the following active pharmaceutical ingredients in parts by weight: 5-25g of perilla leaf, 5-25g of tatarian aster root, 5-25g of Chinese thorowax root, 5-25g of schizonepeta spike, 5-25g of great burdock achene, 5-25g of apricot seed and 1-15g of liquoric root. The active pharmaceutical ingredients can be matched with excipients and a flavoring agent to be directly or indirectly prepared into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of formulations via conventional process steps. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, adenovirus, parainfluenza virus, enteric cytopathogenichuman orphan virus, Coxsackie virus and the like.

The invention relates to a herba tripterospermi, honeysuckle and fructus forsythiae detoxifying and inflammation-diminishing composition for treating cold, pneumonia, enteritis and nephritis. The herba tripterospermi, honeysuckle and fructus forsythiae detoxifying and inflammation-diminishing composition is prepared from, by mass, 10-20 parts of herba tripterospermi, 10-20 parts of flos lonicerae,20-40 parts of fructus forsythiae, 10-20 parts of fructus gardeniae or gardenia jasminoides, 10-20 parts of cortex eucommiae or folium cortex eucommiae, 10-20 parts of saururus chinensis and 10-20 parts of seville orange flowers, and an appropriate amount of pharmaceutic adjuvants. When the disease suddenly occurs, a patient mainly has the symptoms of upper respiratory virus infection history, abdominal distension or enteritis diarrhea or vomiting, nephritis and the like, and the natural course of the disease is 7-14 days. The characteristics and advantages of traditional Chinese medicine treatment of pneumonia accompanied by dialectical therapy and disease and symptom combination of enteritis and nephritis are brought into play, and the invention provides a preparation method of the herba tripterospermi, honeysuckle and fructus forsythiae detoxifying and inflammation diminishing composition for treating cold, pneumonia, enteritis and nephritis and application of the composition in preparation of the medicine for treating cold, pneumonia, enteritis and nephritis. The invention provides a new preparation process, specific new application and new efficacy of the tripterospermum tenuifolium and lonicera and forsythia detoxifying and inflammation-diminishing composition.

Field of application: the invention relates to biotechnology, can be used in the food industry, medicine and cosmetology in the prevention and/or treatment of diseases associated with immunodeficiencies and respiratory viral infections.

The proposed food, cosmetic and pharmaceutical composition with an immunomodulating and protective antiviral effect additionally has the ability to completely prevent infection by a number of viruses, including influenza, rotavirus and coronavirus, as well as stimulate the immune system more than individual probiotics.

Double-stranded siRNA molecules and uses thereof are disclosed herein, wherein each strand of the siRNA molecule is about 15 to about 50 nucleotides, and wherein one strand of the siRNA molecule includes a Nucleic acid sequences with identical conserved sites or variants in nucleic acid sequences.

Belonging to the field of traditional Chinese medicines, the invention discloses application of Forsythoside A in preparation of an anti-influenza A H1N1 virus medicine and a preparation thereof. In vivo pharmacodynamic experimental study on the Forsythoside A provided in the invention in treatment of respiratory virus infection and in vitro anti-respiratory virus pharmacodynamic experimental study on the Forsythoside A show that the Forsythoside A has an obvious inhibiting effect on influenza A H1N1 viruses.

The present invention provides a throat swab collection and protection device for reducing a risk of respiratory virus infection. The throat swab collection and protection device for reducing the riskof the respiratory virus infection comprises an operating table, a thin membrane and an adjustment assembly; operating holes are arranged in the operating table; the thin membrane is connected with operating gloves, the thin membrane covers the operating table, one side, close to the thin membrane, of the operating table is a patient side, one side, away from the thin membrane, of the operating table is an operating side, and the operating gloves can extend into the operating holes to conduct throat swab collection; and the adjustment assembly is connected with the thin membrane, so that theadjustment assembly can adjust the thin membrane to move along the operating table. The provided throat swab collection and protection device for reducing the risk of the respiratory virus infection can effectively reduce the risk of the infection of medical staff during throat swab collection.

The invention relates to the field of pharmacy, and especially relates to a traditional Chinese medicine compound for treating acute respiratory virus infection, a preparation method and medicine box thereof. The traditional Chinese medicine compound preparation is composed of the following traditional Chinese herbals in parts by weight: 8 to 12 parts of flos lonicerae, 8 to 12 parts of chrysanthemum, 5 to 8 parts of fructus forsythiae, 2 to 4 parts of dried orange peel, 4 to 6 parts of haw, and 4 to 6 parts of bitter almond. The preparation method comprises the following steps: step one, extracting flos lonicerae, chrysanthemum, fructus forsythiae, and dried orange peel through a water steam distillation method or a supercritical extraction method so as to obtain volatile oil and aromatic water, saving the volatile oil and aromatic water for later use; boiling the raw materials mentioned above in water, filtering, vacuum-condensing the filtrate, and drying so as to obtain an extract I; step two, boiling haw and bitter almond in water, filtering, vacuum-condensing the filtrate, and drying so as to obtain an extract II; step three, mixing the extract I and the extract II so as to obtain a general extract; step four, mixing the general extract with the volatile oil and aromatic water obtained in the step one and medicinal auxiliary materials, and finally making the mixture into medicinal dosage forms. The traditional Chinese medicine compound preparation can be used to treat acute respiratory virus infection.

The invention discloses a chicken feed. The chicken feed comprises the following ingredients in parts by weight: 10 to 20 parts of corn, 5 to 10 parts of wheat bran, 15 to 20 parts of rice, 2 to 4 parts of colleseed oil, 3 to 6 parts of sesame cake, 1 to 3 parts of edible salt, 1 to 3 parts of fructus forsythiae, 2 to 4 parts of burclover, 1 to 2 parts of astragalus membranaceus, 1 to 3 parts of herba andrographitis, 1 to 2 parts of mint and 1 to 2 parts of liquorice. The chicken feed has the beneficial effects that when the chicken is fed by the feed produced by utilizing the formula, the chicken and egg products have the characteristics of high nutritional value and balanced nutrients; by utilizing the traditional Chinese herbs such as fructus forsythiae, burclover, astragalus membranaceus, herba andrographitis, mint and liquorice, on the one hand, the consumption of antibiotic drugs and additives can be reduced, and on the other hand, the chicken feed can be used for clearing away the heat, relieving the toxicity, inhibiting the respiratory virus infection and other syndrome, so that the immunity of the chicken can be improved, the loss is reduced, and the harm on the human body after people eat the chicken can be reduced.

The invention discloses an application of iodine in preparation of a medicine for preventing and treating respiratory tract infectious diseases and a method for preparing iodine-containing aerosol with low particle size. According to the invention, iodine is dissolved in pure water and an oily solvent to respectively prepare two iodine solution atomizing agents, and the two iodine solution atomizing agents are atomized into iodine-containing aerosol by an atomizer to be inhaled into the respiratory tract, so that pathogens are quickly and efficiently killed, and the iodine-containing aerosol becomes the only specific medicine for treating respiratory virus infection lacking effective treatment medicines; and more effective and convenient treatment medicines are provided for infection of respiratory bacteria, mycoplasmas, fungi and the like. The method is mainly characterized in that iodine is prepared into a low-concentration iodine solution and atomized into iodine-containing aerosol, so that the density of iodine is greatly reduced, the irritation is greatly reduced, and iodine molecules enter the respiratory tract to kill pathogens; the iodine-containing aerosol with low particle size can reach pulmonary alveoli to directly screen and kill viruses in the pulmonary alveoli, so that critical and severe pulmonary infection patients can be quickly out of danger, and mild diseases can be quickly cured.

An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.

A nanoparticle comprising an outer surface comprising a plasma membrane derived from a cell that can be infected with a respiratory virus, including a human lung epithelial cell expressing ACE-2 receptor. Methods of manufacture and use for preventing or treating viral infections, such as coronavirus infection in a subject in need are disclosed.

The invention provides an interleukin 37-based early warning of respiratory virus infection (risk). Specifically, the invention provides an application of a substance for detecting the level of interleukin 37 in a sample in preparation of a product (such as a kit or a detection system) for prognosis evaluation of respiratory virus infection, and a corresponding product, system and method thereof. According to the application, the interleukin 37 is taken as a basic evaluation index, the accuracy and the specificity of severe case prediction are remarkably improved, the severe case occurrence rate and the death rate after respiratory virus infection can be effectively reduced, and the method has important clinical application value and wide application prospect.

The invention particularly relates to a composition for respiratory viruses and a method for preventing and treating the respiratory viruses. Respiratory virus infection is very common clinically, but at present, therapeutic drugs aiming at virus infection cannot meet therapeutic requirements. The invention provides the inhalant for inhibiting respiratory viruses, prevention and treatment are carried out in a manner of inhaling high-temperature acetic acid steam, and acetic acid in the high-temperature steam can be used for inactivating the viruses in the respiratory tract by releasing hydrogen ions, so that the effects of prevention and even treatment are realized before diseases occur. In addition, the composition can also be used for inhibiting fungi and bacteria in vitro and preventing skin diseases and respiratory diseases caused by the bacteria and the fungi. The prevention and treatment method is easy to implement and economical in cost, and has important clinical application value in popularization and application.

The invention discloses an arbidol hydrochloride injection preparation. The injection preparation is prepared from an active ingredient arbidol hydrochloride, a pharmaceutically acceptable co-solventand a buffer solution. The invention further discloses a preparation method of the arbidol hydrochloride injection preparation. The preparation method comprises the following steps: adding the buffersolution and the co-solvent, performing uniform stirring, and slowly and uniformly adding arbidol hydrochloride into the mixture to sufficiently dissolve the arbidol hydrochloride in the mixture; adjusting the pH value of the mixture, adding activated carbon into the mixture, and performing uniform stirring; performing decarbonization, filtering filtrate through a microfiltration membrane, fillinga sterilized ampoule with the filtrate, and sealing the sterilized ampolue; and finally, performing water-bath sterilization. The arbidol hydrochloride injection preparation is applicable to intramuscular injection and is mainly used for preventing and treating type A and type B influenza and other acute respiratory virus infections. The injection preparation can be used for improving the bioavailability of the arbidol hydrochloride, prolonging the administration time, effectively reducing cross contamination, improving the stability of the injection preparation and facilitating clinical application.

The invention relates to application of glucocorticoid in preparation of a medicine for treating and/or preventing respiratory virus infection. The respiratory viruses are selected from SARS-CoV virus, SARS-CoV-2 virus, Middle East respiratory syndrome coronavirus, influenza virus, measles virus, parotitis virus, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, Hendea virus, Nipie virus, rubella virus, rhinovirus, adenovirus, reovirus, coxsackie virus and ECHO virus.